Key result
The J-MELODIC trial is an ongoing randomized study designed to evaluate whether the long-acting loop diuretic azosemide improves prognosis compared to short-acting furosemide in heart failure.
Why the study?
Does azosemide reduce a composite of cardiovascular death and unplanned admission to hospital for congestive HF compared to furosemide in patients with heart failure?
Population
300 patients with heart failure (HF)
Comparison
Azosemide (long-acting loop diuretic) vs Furosemide (short-acting loop diuretic)
Design
RCT, randomized
Follow-up
minimum of 2 years
Authors
Loading...
J-MELODIC results are awaited to guide loop diuretic selection in HF; leaves open whether long-acting agents improve prognosis over short-acting ones.
RCT (n=300)
Open-label
1:1
Yes
Does azosemide reduce a composite of cardiovascular death and unplanned admission to hospital for congestive HF compared to furosemide in patients with heart failure?
This study design outlines a trial to compare the long-term therapeutic effects of long-acting versus short-acting loop diuretics in heart failure patients.
The J-MELODIC Program Committee (2007) conducted an RCT in Heart Failure (n=300). Azosemide vs. Furosemide 20-40 mg/day (up to 80 mg/day) was evaluated on Composite of cardiovascular death and unplanned admission to hospital for congestive HF. The J-MELODIC trial is an ongoing randomized study designed to evaluate whether the long-acting loop diuretic azosemide improves prognosis compared to short-acting furosemide in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: